PHASE I TRIAL--ESCALATING DOSES OF CONTINUOUS INFUSION OF TOPOTECAN & ETOPOSIDE

I 期试验——增加拓扑替康持续输注剂量

• 批准号: 3766294
• 负责人: JOHN ECKARDT
• 金额: --
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3766294
• 关键词: DNA topoisomerases; antineoplastics; camptothecin; clinical trials; combination cancer therapy; combination chemotherapy; dosage; drug screening /evaluation; enzyme inhibitors; etoposide; human subject; human therapy evaluation; neoplasm /cancer chemotherapy

The purpose of this protocol is to attempt to discover if the combination of topotecan, a Topoisomerase I inhibitor, and etoposide, a Topoisomerase II inhibitor, will have a synergistic effect on cytotoxicity.

该协议的目的是尝试发现是否 拓扑异构酶 I 抑制剂拓扑替康和依托泊苷的组合， 拓扑异构酶 II 抑制剂，将产生协同作用 细胞毒性。